Research programme: infectious disease therapeutics - NanoAxis

Drug Profile

Research programme: infectious disease therapeutics - NanoAxis

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoAxis
  • Developer Centre for Disease Control; NanoAxis
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Ebola virus infections; Influenza virus infections

Most Recent Events

  • 18 Jul 2016 Research programme: infectious disease therapeutics - NanoAxis is available for licensing - http://www.nanoaxisllc.com/Immunology.html
  • 18 Jul 2016 Preclinical trials in Ebola virus infections in USA (Parenteral)
  • 18 Jul 2016 Preclinical trials in Influenza virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top